Selected article for: "acute illness and lung infection"
Author: Shetty, Ashok K
Title: Mesenchymal Stem Cell Infusion Shows Promise for Combating Coronavirus (COVID-19)- Induced Pneumonia
  • Cord-id: v73bsrwg
  • Document date: 2020_3_9
    • ID: v73bsrwg
    Snippet: A new study published by the journal Aging & Disease reported that intravenous administration of clinical-grade human mesenchymal stem cells (MSCs) into patients with coronavirus disease 2019 (COVID-19) resulted in improved functional outcomes (Leng et al., Aging Dis, 11:216-228, 2020). This study demonstrated that intravenous infusion of MSCs is a safe and effective approach for treating patients with COVID-19 pneumonia, including elderly patients displaying severe pneumonia. COVID-19 is a seve
    Document: A new study published by the journal Aging & Disease reported that intravenous administration of clinical-grade human mesenchymal stem cells (MSCs) into patients with coronavirus disease 2019 (COVID-19) resulted in improved functional outcomes (Leng et al., Aging Dis, 11:216-228, 2020). This study demonstrated that intravenous infusion of MSCs is a safe and effective approach for treating patients with COVID-19 pneumonia, including elderly patients displaying severe pneumonia. COVID-19 is a severe acute respiratory illness caused by a new coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Currently, treating COVID-19 patients, particularly those afflicted with severe pneumonia, is challenging as no specific drugs or vaccines against SARS-CoV-2 are available. Therefore, MSC therapy inhibiting the overactivation of the immune system and promoting endogenous repair by improving the lung microenvironment after the SARS-CoV-2 infection found in this study is striking. Additional studies in a larger cohort of patients are needed to validate this therapeutic intervention further, however.

    Search related documents:
    Co phrase search for related documents
    • acute kidney injury and low oxygen saturation: 1
    • acute kidney injury and lung alveolar: 1, 2, 3, 4, 5
    • acute kidney injury and lung alveolar type ii: 1, 2
    • acute kidney injury and lung alveolar type ii cell: 1
    • acute kidney injury and lung function: 1, 2, 3, 4, 5, 6, 7, 8
    • acute kidney injury and lung infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • acute kidney injury and lupus erythematosus: 1, 2, 3
    • acute respiratory distress and additional study: 1, 2, 3, 4, 5, 6, 7, 8
    • acute respiratory distress and low oxygen saturation: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • acute respiratory distress and lung alveolar: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory distress and lung alveolar type ii: 1, 2, 3, 4, 5, 6, 7
    • acute respiratory distress and lung alveolar type ii cell: 1
    • acute respiratory distress and lung function: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory distress and lung function improve: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • acute respiratory distress and lung infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory distress and lung microenvironment: 1, 2, 3, 4, 5, 6
    • acute respiratory distress and lupus erythematosus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
    • acute respiratory distress syndrome and additional study: 1, 2, 3, 4, 5, 6, 7
    • acute respiratory distress syndrome and low oxygen saturation: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10